📰 Trepl News
Page 6 - Trepl News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Trepl. Real-time updates on events, politics, business and more.
March 24, 2023
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) fell 3.8% during trading on Wednesday . The company traded as low as $19.24 and last traded at $19.24. 16,801 shares changed hands during trading, a decline of 97% from the average session volume of 567,215 shares. The stock had previously closed at $20.00. Analyst Upgrades and Downgrades […]
January 3, 2023
Change in the Calendar Doesn't Change the Character of the Market...REPL
December 14, 2022
Replimune (REPL) Breaks Out: Could Rise 30% From Here...REPL
November 16, 2022
It may be noted that BJP national vice president Dilip Ghosh’s property deed was found in the house of Prasanna Ray, an arrested middleman in the SSC scam.
October 31, 2022
An AI pair programmer that helps you write better code, faster.
June 6, 2022
A number of firms have modified their ratings and price targets on shares of Replimune Group (NASDAQ: REPL) recently: 5/25/2022 – Replimune Group was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes […]
May 27, 2022
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) – Analysts at Wedbush issued their FY2024 earnings per share estimates for shares of Replimune Group in a research note issued to investors on Tuesday, May 24th. Wedbush analyst R. Driscoll anticipates that the company will earn ($2.77) per share for the year. Wedbush currently has a “Outperform” […]
May 25, 2022
Replimune Group (NASDAQ:REPL – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of […]
May 19, 2022
Replimune Group (NASDAQ:REPL – Get Rating) had its price target reduced by Piper Sandler from $52.00 to $44.00 in a report issued on Thursday, The Fly reports. Piper Sandler’s price objective would suggest a potential upside of 201.16% from the stock’s previous close. A number of other brokerages have also recently commented on REPL. BMO […]